Arvinas Inc ARVN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ARVN is a good fit for your portfolio.
News
-
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
-
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact
-
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
-
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
-
Arvinas to Participate in Upcoming Investor Conferences
-
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Arvinas Announces Chief Financial Officer Transition
-
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
Trading Information
- Previous Close Price
- $31.60
- Day Range
- $31.04–32.72
- 52-Week Range
- $13.57–53.08
- Bid/Ask
- $30.61 / $33.80
- Market Cap
- $2.21 Bil
- Volume/Avg
- 778,697 / 773,618
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 22.34
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 445
- Website
- https://www.arvinas.com
Comparables
Valuation
|
Metric
|
ARVN
|
VOR
|
ERAS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.26 | 0.77 | 0.88 |
Price/Sales | 22.34 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ARVN
VOR
ERAS
Financial Strength
|
Metric
|
ARVN
|
VOR
|
ERAS
|
|---|---|---|---|
Quick Ratio | 4.93 | 8.81 | 11.94 |
Current Ratio | 4.98 | 9.04 | 12.26 |
Interest Coverage | — | — | — |
Quick Ratio
ARVN
VOR
ERAS
Profitability
|
Metric
|
ARVN
|
VOR
|
ERAS
|
|---|---|---|---|
Return on Assets (Normalized) | −26.31% | −41.83% | −22.08% |
Return on Equity (Normalized) | −58.35% | −51.69% | −27.20% |
Return on Invested Capital (Normalized) | −63.59% | −47.03% | −27.50% |
Return on Assets
ARVN
VOR
ERAS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lspxzsssfq | Cmbt | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Txlxzqsd | Yjbktkz | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qzjdsxrpz | Nxrlxs | $97.8 Bil | |
MRNA
| Moderna Inc | Dccjzpdw | Tnff | $38.8 Bil | |
ARGX
| argenx SE ADR | Tjmgvlwkq | Yhby | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Lhyqvhyzf | Bgjj | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ktgbmwvlx | Phkzjfl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vllfsmwn | Tdyrww | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lypksyvpf | Vqvgw | $12.5 Bil | |
INCY
| Incyte Corp | Rmjdtsjt | Gtljwn | $11.5 Bil |